a trend toward significanceP = 0.07
Similar findings were reported for alendronate in a post hoc analysis of the FIT trial [ 41 ], in which there was a trend toward significance for atrial fibrillation (47 events [1.5%] with alendronate vs. 31 events [1.0%] with placebo, P = 0.07).